2. Search Result
Search Result
Results for "

PC-3 prostate tumor

" in MedChemExpress (MCE) Product Catalog:

24

Inhibitors & Agonists

4

Peptides

4

Natural
Products

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-130709
    PROTAC CDK2/9 Degrader-1

    		PROTACs CDK Cancer
    PROTAC CDK2/9 Degrader-1 (Compound F3) is a potent dual degrader for CDK2 (DC50=62 nM) and CDK9 (DC50=33 nM). PROTAC CDK2/9 Degrader-1 suppresses prostate cancer PC-3 cell proliferation (IC50=0.12 µM) by effectively blocking the cell cycle in S and G2/M phases. PROTAC CDK2/9 Degrader-1 is a PROTAC by tethering CDK inhibitor with Cereblon ligand .
    PROTAC CDK2/9 Degrader-1
  • HY-16160
    Cysmethynil
    1 Publications Verification

    		 Autophagy ICMT Neurological Disease Cancer
    Cysmethynil is an Icmt inhibitor(IC50 = 2.4 μM). Cysmethynil inhibites RAS membrane binding and EGF signal transduction. Cysmethynil prevents the cells in the G1 phase and induces autophagy. Cysmethynil inhibits PC3 cells proliferation, has synergistic effect with Paclitaxel (HY-B0015) and Doxorubicin (HY-15142A). Cysmethynil has anti-tumor effects and can be used for solid tumor (such as prostate cancer et al.) research .
    Cysmethynil
  • HY-P1793
    α-Casein (90-95)

    		Opioid Receptor Biochemical Assay Reagents Neurological Disease Inflammation/Immunology Cancer
    α-Casein (90-95) is a partial agonist of opioid receptors and a copper ion ligand, with opioid activity. α-Casein (90-95) inhibits the secretion of β-hexosaminidase by rat peritoneal mast cells (PMC) with IC50= 0.1 μM. α-Casein (90-95) inhibits the proliferation of prostate cancer cells LNCaP, DU145, and PC3 with IC50 of 0.94 nM, 137 nM, and 6.92 nM, respectively. α-Casein (90-95) activates Gi-like proteins through a membrane-assisted, receptor-independent pathway, or reversibly binds to opioid receptors, inducing intracellular calcium release and conformational changes, and exerts the activity of promoting mast cell secretion and inhibiting tumor cell proliferation. α-Casein (90-95) can be used in the study of the mechanisms of allergic diseases and prostate cancer .
    α-Casein (90-95)
  • HY-N15686
    Torulene

    Torulin

    		 Apoptosis Androgen Receptor Bcl-2 Family MMP Cancer
    Torulene (Torulin) is an orally active carotenoid with anti-cancer activity. Torulene inhibits proliferation and induces apoptosis of tumor cells via a mitochondrial signal pathway and the down-regulation of androgen receptor (AR) expression. Torulene can be used for the study of prostate cancer .
    Torulene
  • HY-147696
    SMTIN-T140

    		HSP AMPK Reactive Oxygen Species (ROS) Cancer
    SMTIN-T140 (compound 6a) is a potent TRAP1 (tumor-necrosis-factor-receptor associated protein 1) inhibitor, with an IC50 of 1.646 μM. SMTIN-T140 shows anticancer activity. SMTIN-T140 leads to mitochondrial dysfunction, increases mitochondrial ROS production and activates AMPK. SMTIN-T140 potently suppressed tumor growth without any noticeable in vivo toxicity in a mouse model xenografted with PC3 prostate cancer cells .
    SMTIN-T140
  • HY-178489
    BGC1614

    		Nectin-4 Cancer
    BGC1614 is a Nectin-4-targeting bicyclic toxin conjugate (BTC) belonging to the category of peptide-drug conjugates (PDCs). BGC1614 exhibits strong targeted binding ability to Nectin-4, with an KD of 3.859 × 10 -7 M. BGC1614 exhibits superior antitumor efficacy in nude mice bearing PC-3 and N87 tumor xenografts. BGC1614 can be used for research related to Nectin-4-overexpressing tumors (such as prostate cancer, gastric cancer) .
    BGC1614
  • HY-178045
    MYC-IN-4

    		c-Myc Cancer
    MYC-IN-4 is a MYC inhibitor. MYC-IN-4 impairs MYC/MAX protein-protein interaction (IC50 = 3.06 μM). MYC-IN-4 inhibits MYC-aberrant PC-3 prostate cancer cells with an IC50 of 0.440 μM. MYC-IN-4 demonstrates potent antitumor efficacy in FVB mice bearing Myc-CaP prostate tumor allografts. MYC-IN-4 can be used for the study of prostate cancer .
    MYC-IN-4
  • HY-175017
    Survivin-IN-2

    		Survivin Cancer
    Survivin-IN-2 is a survivin inhibitor. Survivin-IN-2 shows cytotoxicity in cells with IC50s of 0.53 μM (C4-2 cells) and 1.06 μM (PC-3 cells). Survivin-IN-2 effectively suppresses xenograft tumor growth without apparent toxicity and eliminates survivin in the tumors. Survivin-IN-2 can be used for the study of prostate cancer .
    Survivin-IN-2
  • HY-163683
    EB-PSMA-617

    		Radionuclide-Drug Conjugates (RDCs) PSMA Cancer
    EB-PSMA-617 is a modified form of PSMA-617 that has enhanced pharmacokinetic properties by conjugating it to Evans Blue (EB) to extend its circulation half-life to improve prostate tumor uptake and radiotherapy efficacy. In preclinical studies using PC3-PIP-loaded mice, EB-PSMA-617 demonstrated prolonged blood half-life, increased accumulation in PSMA-positive tumors, and successful tumor elimination with lower radioactivity .
    EB-PSMA-617
  • HY-131438
    GI-149893

    		Topoisomerase Cancer
    GI-149893 is a selective topoisomerase I (TopoI) inhibitor. GI-149893 prevents DNA religation and induces irreversible DNA damage in tumor cells. GI-149893 is promising for research of cancers (e.g., colon carcinoma HT-29/SW-48, breast MX-1, prostate PC-3 xenografts) .
    GI-149893
  • HY-175826
    USP30-IN-20

    		Deubiquitinase Ferroptosis Reactive Oxygen Species (ROS) Glutathione Peroxidase Cancer
    USP30-IN-20 is an orally active USP30 inhibitor (Kd = 1.61 μM, IC50 = 12.8 μM). USP30-IN-20 induces ferroptosis by promoting ubiquitination-mediated degradation of GPX4. USP30-IN-20 inhibits the proliferation, migration, invasion, and stemness of prostate cancer cells. USP30-IN-20 induces G0/G1 cell cycle arrest and ROS levels in prostate cancer cells. USP30-IN-20 exhibits significant anti-tumor efficacy in PC3 cell subcutaneous xenografts in mice. USP30-IN-20 can be used for the study of advanced prostate cancer .
    USP30-IN-20
  • HY-P1793A
    α-Casein (90-95) TFA

    		Opioid Receptor Biochemical Assay Reagents Neurological Disease Inflammation/Immunology Cancer
    α-Casein (90-95) TFA is a partial agonist of opioid receptors and a copper ion ligand, with opioid activity. α-Casein (90-95) TFA inhibits the secretion of β-hexosaminidase by rat peritoneal mast cells (PMC) with IC50= 0.1 μM. α-Casein (90-95) TFA inhibits the proliferation of prostate cancer cells LNCaP, DU145, and PC3 with IC50 of 0.94 nM, 137 nM, and 6.92 nM, respectively. α-Casein (90-95) TFA activates Gi-like proteins through a membrane-assisted, receptor-independent pathway, or reversibly binds to opioid receptors, inducing intracellular calcium release and conformational changes, and exerts the activity of promoting mast cell secretion and inhibiting tumor cell proliferation. α-Casein (90-95) TFA can be used in the study of the mechanisms of allergic diseases and prostate cancer .
    α-Casein (90-95) TFA
  • HY-175555
    Tubulin-IN-54

    		Microtubule/Tubulin Apoptosis Cancer
    Tubulin-IN-54 is a tubulin inhibitor. Tubulin-IN-54 exhibits anti-proliferative activity against various cancer cells. Tubulin-IN-54 inhibits tubulin polymerization, disrupts microtubule networks, induces G2/M cell cycle arrest, and promotes cancer cell apoptosis. Tubulin-IN-54 demonstrates significant anti-tumor efficacy in mice bearing PC-3/TxR xenografts. Tubulin-IN-54 can be used for the study of taxane-resistant cancers (prostate cancer, melanoma) .
    Tubulin-IN-54
  • HY-169414
    WRN inhibitor 15

    		DNA/RNA Synthesis Cancer
    WRN inhibitor 15 (Compound 9) is a WRN inhibitor with anti-tumor activity that can be used in prostate cancer research, the IC50 values are 37.9, 40.2 and 46.6 μM in PC3, LNCaP, and HeLa .
    WRN inhibitor 15
  • HY-N16426
    Mycoleptone A

    		Parasite Infection Cancer
    Mycoleptone A is an azafluorenone compound. Mycoleptone A exhibits certain anti-leishmanial activity, with an LD50 of 28.5 μM against L. major. Mycoleptone A shows cytotoxicity against human prostate cancer cell line PC3, with an IC50 of 10.0 μM. Mycoleptone A can be used in research on anti-parasitic and anti-tumor aspects .
    Mycoleptone A
  • HY-168300
    Antiangiogenic agent 7

    		Reactive Oxygen Species (ROS) Apoptosis Inflammation/Immunology Cancer
    Antiangiogenic agent 7 (Compound 1) can induce cell apoptosis, increase Reactive Oxygen Species, and inhibit the intracellular enzyme thioredoxin reductase. Antiangiogenic agent 7 has anti-cancer activity, with an IC50 of 0.08-3.5 μM against cervical cancer cells HeLa, prostate cancer cells PC-3, and non-small cell lung cancer A549. Antiangiogenic agent 7 inhibits tumor growth in mouse xenograft models .
    Antiangiogenic agent 7
  • HY-169078
    ML234

    		Histone Methyltransferase Cancer
    ML234 is a dual inhibitor against EZH2/LSD1 with IC50 values of 0.09 and 0.12 μM, respectively. ML234 displays an excellent antiproliferative capacity against prostate cancer cell lines LNCAP, PC3 and 22RV1. ML234 suppresses the tumor growth in the 22RV1 xenograft mouse model. ML234 is promising for research of anticancer agents in prostate cancer .
    ML234
  • HY-162895
    NL13

    		Polo-like Kinase (PLK) Akt CDK Caspase Apoptosis Cancer
    NL13 is a Polo-like kinase 4 (PLK4) inhibitor with an IC50 value of 2.32 μM. NL13 can inhibit the viability of PC3 and DU145 prostate cancer cells, with IC50 values of 3.51 μM and 2.53 μM, respectively. NL13 can lead to the inactivation of the AKT signaling pathway by downregulating CCNB1/CDK1, inducing G2/M cell cycle arrest, and triggering apoptosis through the cleavage of caspase-9/caspase-3. In prostate cancer mice, NL13 can inhibit tumor growth .
    NL13
  • HY-174451
    KMT9-IN-2

    		Epigenetic Reader Domain Cancer
    KMT9-IN-2 (Compound 7b) is an active form of a KMT9 inhibitor (Kd of 10 nM). KMT9-IN-2 can be used in the research of colon cancer .
    KMT9-IN-2
  • HY-174450
    KMT9-IN-1

    		Epigenetic Reader Domain Cancer
    KMT9-IN-1 (Compound 8) is a KMT9 inhibitor and the ethyl ester prodrug of compound 7b. KMT9-IN-1 releases the active form 7b via esterases in cells. KMT9-IN-1 targets KMT9 in cells and reduces H4K12me1 levels. KMT9-IN-1 has antitumor activity against colon cancer. KMT9-IN-1 can be used in the research of prostate cancer and hepatocellular carcinoma .
    KMT9-IN-1
  • HY-W753557
    Avocadene

    		Drug Derivative Insecticide Bacterial Infection Inflammation/Immunology Cancer
    Avocadene is a natural product isolated from Persea americana leaves, with anticancer, insecticidal, anti-Helicobacter pylori, and anti-inflammatory activity. Avocadene exerts antibacterial and anti‑inflammatory effects by suppressing Helicobacter pylori growth and inhibiting protein denaturation. Avocadene displays obvious cytotoxic activity against human prostate cancer PC‑3 cells with an IC50 of 0.5 μg/mL. Avocadene can be used for research of Helicobacter pylori‑associated gastrointestinal inflammation, gastroduodenal injury and prostate tumors .
    Avocadene
  • HY-180995
    VARS1-IN-1

    		DNA/RNA Synthesis Cancer
    VARS1-IN-1 is a valyl-tRNA synthetase (VARS1) inhibitor with a Kd of 0.213 μM. VARS1-IN-1 suppresses VARS1’s tRNA aminoacylation activity, reduces charged levels of valine tRNAs and redues total protein synthesis rate. VARS1-IN-1 suppresses aggressive tumor growth and cell proliferation in PC3 prostate cancer xenograft models. VARS1-IN-1 can be used for the research of prostate cancer .
    VARS1-IN-1
  • HY-P11768
    AMBA

    		Bombesin Receptor Cancer
    AMBA is a gastrin-releasing peptide receptor (GRPR, BB2, BRS-2) ligand. AMBA binds to GRPR with high specificity and high affinity, and undergoes receptor-mediated endocytosis, which retains the conjugated radiometal in target cells. AMBA is applicable for the research of prostate cancer .
    AMBA
  • HY-N17406
    Dankasterone A

    		Endogenous Metabolite Fungal Heme Oxygenase (HO) Apoptosis Reactive Oxygen Species (ROS) Cancer
    Dankasterone A is a secondary metabolite. Dankasterone A can be derived from the Fungus Talaromyces purpurogenu. Dankasterone A upregulates HO-1 protein expression, induces Apoptosis, induces excessive ROS production. Dankasterone A has anti-cancer activity against prostate cancer .
    Dankasterone A

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: